WO2011100325A2 - Polymorphes de sels de sunitinib - Google Patents

Polymorphes de sels de sunitinib Download PDF

Info

Publication number
WO2011100325A2
WO2011100325A2 PCT/US2011/024194 US2011024194W WO2011100325A2 WO 2011100325 A2 WO2011100325 A2 WO 2011100325A2 US 2011024194 W US2011024194 W US 2011024194W WO 2011100325 A2 WO2011100325 A2 WO 2011100325A2
Authority
WO
WIPO (PCT)
Prior art keywords
sunitinib
ray powder
powder diffraction
crystalline form
theta
Prior art date
Application number
PCT/US2011/024194
Other languages
English (en)
Other versions
WO2011100325A3 (fr
Inventor
Pavel Vraspir
Maurizio Paiocchi
Alexandr Jegorov
Francesca Scarpitta
Original Assignee
Sicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Inc. filed Critical Sicor Inc.
Publication of WO2011100325A2 publication Critical patent/WO2011100325A2/fr
Publication of WO2011100325A3 publication Critical patent/WO2011100325A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to polymorphs of Sunitinib malate
  • compositions comprising Sunitinib base, L-malic acid and another carboxylic acid; the preparation thereof and pharmaceutical compositions thereof.
  • sunitinib salts such as sunitinib malate of the following formula:
  • Sunitinib malate is a multi-kinase inhibitor marketed in the United
  • SUTENT ® is approved by the FDA for the treatment of gastrointestinal stromal tumor after disease progression or on intolerance to imatinib mesylate, and for the treatment of advanced renal cell carcinoma.
  • SUTENT ® is available as hard-shell capsules containing an amount of sunitinib malate that is equivalent to 12.5 mg, 25 mg, or 50 mg of sunitinib.
  • the capsules contain sunitinib malate together with the inactive ingredients mannitol, croscarmellose sodium, povidone (K-25) and magnesium stearate.
  • U.S. patent No. 6,573,293 (“'293 patent”) refers to the preparation of sunitinib base and salts thereof, as well as the use of these salts.
  • the '293 patent refers to the synthesis of sunitinib base by condensing
  • WO 2009/067686 A2 WO 2009/156837 A2 and WO 2010/010454 A2 describe solid state forms of Sunitinib malate and preparation thereof.
  • PCT Publication Nos. WO 2009/067674 A2, WO 2009/074862 Al, WO 2009/109388 Al and WO 2009/128083 Al describe solid state forms of Sunitinib base and preparation thereof.
  • WO 2010/01 1834 A2 describes solid state forms of Sunitinib acetate and a preparation thereof.
  • PCT Publication WO 2010/049449 describes solid state forms of Sunitinib D-tartarate, L-tartarate, citrate and preparation thereof.
  • Atty Docket No. 70175.0023WOU1 give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviours (e.g. measured by thermogravimetric analysis - "TGA”, or differential scanning calorimetry - “DSC”), x-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum.
  • TGA thermogravimetric analysis -
  • DSC differential scanning calorimetry -
  • Discovering new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., better processing or handling characteristics, improved dissolution profile, or improved shelf-life. For at least these reasons, there is a need for additional polymorphs of Sunitinib and sunitinib salts.
  • the present invention provides solid state physical properties of racemic Sunitinib malate; other salts of Sunitinib; and compositions comprising Sunitinib base, L-malic acid and other carboxylic acid.
  • the present invention encompasses Sunitinib fumarate, Sunitinib hydrochloride and compositions comprising Sunitinib base, L-malic acid and another carboxylic acid.
  • the present invention encompasses crystalline forms of racemic Sunitinib malate, Sunitinib fumarate, Sunitinib hydrochloride and of compositions comprising Sunitinib base, L-malic acid and another carboxylic acid.
  • the present invention encompasses the use of the above described salts and crystalline forms for the preparation of formulations.
  • the present invention encompasses a pharmaceutical composition comprising the above described salts and crystalline forms, and at least one pharmaceutically acceptable excipient.
  • the present invention encompasses the use of the above described salts and crystalline forms for the preparation sunitinib malate.
  • Figure 1 provides a characteristic X-ray powder diffraction of crystalline racemic sunitinib malate form Al.
  • Figure 2 provides a characteristic X-ray powder diffraction of crystalline racemic sunitinib malate form A2.
  • Figure 3 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and fumaric acid in molar ratio 1 : 1 : 1 (form Gamma 1).
  • Figure 4 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and succinic acid in molar ratio 1 : 1 : 1 (form Gamma 2).
  • Figure 5 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and L-tartric acid in molar ratio 1 : 1 : 1 (form Gamma 3).
  • Figure 6 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and D-tartric acid in molar ratio 1 : 1 : 1 (form Gamma 4).
  • Figure 7 provides a characteristic X-ray powder diffraction
  • composition comprising Sunitinib base, L-malic acid and malonic acid in molar ratio 1 : 1 : 1 (form Gamma 5).
  • Figure 8 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and adipic acid in molar ratio 1 : 1 : 1 (form Gamma 6).
  • Figure 9 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and fumaric acid in molar ratio 1 : 1 : 1 (form Gamma 7).
  • Figure 10 provides a characteristic X-ray powder diffraction of composition comprising Sunitinib base, L-malic acid and fumaric acid in molar ratio 1 : 1 : 1 (form Gamma 8).
  • Figure 11 provides a characteristic X-ray powder diffraction of crystalline Sunitinib fumarate form Delta.
  • Figure 12 provides a detailed view of a solid state 13 C NMR spectrum of Sunitinib fumarate form Delta.
  • Figure 13 provides a full-width solid state 13 C NMR spectrum of Sunitinib fumarate form Delta.
  • Figure 14 provides a characteristic X-ray powder diffraction of sunitinib D,L-malate form B prepared according to Example 12.
  • Figure 15 provides a characteristic X-ray powder diffraction of sunitinib D,L-malate form B prepared according to Example 13.
  • Figure 16 provides a characteristic X-ray powder diffraction of sunitinib D,L-malate form B prepared according to Example 14.
  • Figure 17 provides a characteristic X-ray powder diffraction of sunitinib D,L-malate form B prepared according to Example 15.
  • Figure 18 provides a characteristic X-ray powder diffraction of sunitinib hydrochloride form Epsilon.
  • racemic refers to a mixture that contains an approximately equal amount of enantiomers.
  • Room temperature refers to a temperature between about 20 °C and about 30 °C. Usually, room temperature ranges from about 20°C to about 25 °C.
  • the term “Overnight” refers to a period of between about 15 and about 20 hours, typically between about 16 to about 20 hours.
  • a crystal form may be referred to herein as being characterized by graphical data substantially "as depicted in" a Figure.
  • Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with Patent Application
  • Atty Docket No. 70175.0023WOU1 graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms.
  • Sunitinib hydrochloride and of compositions comprising Sunitinib base, L-malic acid and another carboxylic acid have advantageous properties selected from at least one of: chemical purity, flowability, solubility, morphology or crystal habit, stability - such as storage stability, stability to dehydration, stability to polymorphic conversion, low hygroscopicity, and low content of residual solvents.
  • the present invention provides solid state forms of racemic Sunitinib malate; other salts of Sunitinib; and compositions comprising Sunitinib base, L-malic acid and other carboxylic acid.
  • the present invention includes embodiments that are Sunitinib salts containing two different carboxylate components wherein the ratio between Sunitinib base, a first carboxylic acid and a second carboxylic acid is "about 1 : 1 : 1 (mole: mole: mole)." It will be understood that the molar ratio variation contemplated by the term "about” is ⁇ 5 %.
  • the present invention encompasses a crystalline form of racemic sunitinib malate, designated herein as form Al .
  • Form Al can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.8, 6.4, 7.4, 11.7 and 16.3 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 1 ; and combinations thereof.
  • Racemic sunitinib malate Form Al can be further characterized by additional X-ray powder diffraction peaks at 12.8, 13.5, 24.5 and 25.4 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a crystalline form of racemic sunitinib malate, designated herein as form A2.
  • Form A2 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.2, 6.8, 21.2, 25.1 and 25.6 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 2; and combinations thereof.
  • Racemic sunitinib malate Form A2 can be further characterized by additional X-ray powder diffraction peaks at 8.2, 13.2, 16.3 and 24.2 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a sunitinib salt selected from a group consisting of Sunitinib fumarate; Sunitinib hydrochloride; and compositions comprising Sunitinib base, L-malic acid and another carboxylic acid.
  • the above described salts are provided in an isolated form.
  • the isolated Sunitinib salt is a solid, more preferably, it is crystalline.
  • the term "isolated" in reference to Sunitinib salt corresponds to Sunitinib salt that is physically separated from the reaction mixture where it is formed.
  • the present invention encompasses a crystalline composition comprising Sunitinib base, L-malic acid and fumaric acid; wherein the ratio between Sunitinib base, L-malic acid and fumaric acid is about 1 : 1 : 1 (mole: mole: mole), designated herein as form Gamma 1.
  • Form Gamma 1 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.3, 6.8, 8.2, 10.0 and 15.3 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 3; and combinations thereof.
  • Form Gamma 1 can be further characterized by additional powder XRD peaks at 1 1.0, 13.2, 16.4, 23.3 and 26.7 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a crystalline composition
  • a crystalline composition comprising Sunitinib base, L-malic acid and succinic acid; wherein the ratio between Sunitinib base, L-malic acid and succinic acid is about 1 : 1 : 1 (mole: mole: mole), designated herein as form Gamma 2.
  • Form Gamma 2 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.0, 20.0, 26.1 and 31.5 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 4; and combinations thereof.
  • Form Gamma 2 can be further characterized by additional powder XRD peaks at 12.0, 22.6, 27.2 and 38.0 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a crystalline composition
  • a crystalline composition comprising Sunitinib base, L-malic acid and L-tartaric acid; wherein the ratio between Sunitinib base, L-malic acid and L-tartaric acid is about 1 : 1 : 1
  • Form Gamma 3 can be Patent Application
  • Atty Docket No. 70175.0023WOU1 characterized by data selected from: an X-ray powder diffraction pattern having peaks at 1 1.3, 14.8, 23.1, 24.0 and 27.1 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X- ray powder diffraction pattern substantially as depicted in Figure 5; and combinations thereof.
  • the present invention encompasses a crystalline composition
  • a crystalline composition comprising Sunitinib base, L-malic acid and D-tartaric acid; wherein the ratio between Sunitinib base, L-malic acid and D-tartaric acid is about 1 : 1 : 1
  • Form Gamma 4 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 1 1.3, 14.8, 23.1, 24.0 and 27.1 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X- ray powder diffraction pattern substantially as depicted in Figure 6; and combinations thereof.
  • the present invention encompasses a crystalline composition comprising Sunitinib base, L-malic acid and malonic acid; wherein the ratio between Sunitinib base, L-malic acid and malonic acid is about 1 : 1 : 1 (mole: mole: mole), designated herein as form Gamma 5.
  • Form Gamma 5 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 1 1.5, 14.5, 22.8, 23.9 and 26.9 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X- ray powder diffraction pattern substantially as depicted in Figure 7; and combinations thereof.
  • the present invention encompasses a crystalline composition
  • a crystalline composition comprising Sunitinib base, L-malic acid and adipic acid; wherein the ratio between Sunitinib base, L-malic acid and adipic acid is about 1 : 1 : 1 (mole: mole: mole), designated herein as form Gamma 6.
  • Form Gamma 6 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 21.5, 25.2, 25.7, 31.1 and 37.2 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 8; and combinations thereof.
  • Form Gamma 6 can be further characterized by additional X-ray powder diffraction peaks at 12.1, 12.9, 14.5, 14.9 and 38.3 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a crystalline composition
  • a crystalline composition comprising Sunitinib base, L-malic acid and fumaric acid; wherein the ratio between Sunitinib base, L-malic acid and fumaric acid is about 1 : 1 : 1 (mole: Patent Application
  • Form Gamma 7 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 2.9, 20.0, 26.0 and 31.4 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 9; and combinations thereof.
  • Form Gamma 7, can be further characterized by additional X-ray powder diffraction peaks at 1 1.9, 22.5, 27.2 and 38.0 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention encompasses a crystalline composition comprising Sunitinib base, L-malic acid and fumaric acid; wherein the ratio between Sunitinib base, L-malic acid and fumaric acid is about 1 : 1 : 1 (mole: mole: mole), designated herein as form Gamma 8.
  • Form Gamma 8 can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.0, 9.1, 12.1, 27.0 and 28.5 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 10; and combinations thereof.
  • the present invention encompasses a crystalline Sunitinib fumarate, designated herein as form Delta.
  • Form Delta can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.7, 6.9, 17.8, 18.4 and 20.6 degrees 2-theta ⁇ 0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in Figure 11 ; a solid-state 13 C NMR spectrum with signals at 173.1, 139.8, 135.5 and 1 13.0 ⁇ 0.2 ppm, a solid-state 13 C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 66.4, 33.1, 28.8 and 6.3 ⁇ 0.1 ppm; a 13 C NMR spectrum substantially as depicted in Figure 12, and a solid-state 13 C NMR spectrum substantially as depicted in Figure 13 and
  • Sunitinib fumarate form Delta can be further characterized by data selected from an additional X-ray powder diffraction peaks at 13.6, 20.0, 20.3, 23.1 and 25.4 degrees 2-theta ⁇ 0.2 degrees 2-theta; a solid-state 13 C NMR spectrum having signals at 167.1, 166.7, 128.4 and 1 10.1 ⁇ 0.2 ppm; and a solid-state 13 C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 60.7, 60.0, 21.7 and 3.4 ⁇ 0.1 ppm and combination thereof.
  • the signal exhibiting the lowest chemical shift in the chemical shift area of 100 to 180 ppm is at 106.7 ⁇ 1 ppm.
  • the present invention encompasses a crystalline Sunitinib hydrochloride, designated herein as form Epsilon.
  • Form Epsilon can be characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.5, 11.1, 15.2, 18.4 and 26.2 degrees 2-theta ⁇ 0.2 degrees 2-theta; and an X-ray powder diffraction pattern substantially as depicted in Figure 18; and combinations thereof.
  • Sunitinib hydrochloride form Epsilon can be further characterized by data selected from an additional X-ray powder diffraction peaks at 16.0, 16.5, 20.6, 25.1 and 30.0 degrees 2-theta ⁇ 0.2 degrees 2-theta.
  • the present invention further encompasses 1) a pharmaceutical composition comprising the above described salts and crystalline forms and at least one pharmaceutically acceptable excipient; 2) the use of any one or combination of the above described salts and crystalline forms and another carboxylic acid in the manufacture of a pharmaceutical composition, and 3) a method of treating gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate and for the treatment of advanced renal cell carcinoma, comprising administering a pharmaceutically effective amount of at least one of the above described salts and crystalline forms to a subject in need of the treatment.
  • the pharmaceutical composition can be useful for preparing a medicament.
  • the present invention also provides at least one of the above described salts and crystalline forms for use as a medicament.
  • the present invention encompasses the use of the above described salts and crystalline forms for the preparation sunitinib malate.
  • X'Celerator detector active length (2 theta) 2.122°, laboratory temperature 22-25 °C. Zero background sample holders. Prior to analysis, the samples were gently ground with a mortar and pestle in order to obtain a fine powder.
  • a silicon internal standard can be used to calibrate peak positions and to eliminate effects related to sample preparation.
  • the internal standard possesses a diffraction with defined position at 28.44 degrees 2-theta.
  • the internal standard can be mixed with a sample, X-ray powder diffraction is then acquired and the current position of the aforementioned internal standard diffraction peak is determined. The difference between the current position of the diffraction and its nominal value of 28.44 degrees 2-theta is calculated. The current positions of all relevant sample peaks are then re-calculated by means of the above difference to obtain the true positions of the sample diffractions.
  • Step size 0.0167 °
  • Sample holder quartz plate.
  • Atty Docket No. 70175.0023WOU1 ⁇ ⁇ 2 ⁇ 62.5 kHz and repetition delay was 5 s. The number of scans was 7200.
  • 13 C NMR chemical shifts refers to the shifts measured under above specified conditions; however, these shifts can slightly differ instrument to instrument and can be shifted either upfield or downfield due to the different instrumental setup and calibration used. Nevertheless the sequence of individual peaks remains identical.
  • Sunitinib base (10.0 g) was suspended in a mixture of water (22 mL) and ethanol (45 mL). The mixture was heated to 40°C and solid D, L-malic acid (3.6 g) and ethanol (45 mL) were added. The mixture was heated to 60°C to complete dissolution of malic acid. The obtained solution was cooled to 35°C over 1 hour, and kept at 35°C for half an hour. No crystals formed at this point. The solution was further cooled to 25°C for 1 hour. A copious precipitation occurred. The suspension was cooled to 0°C for 1 hour and the product was separated by filtration (bed filtration), washed with ethanol (20 ml) and dried under vacuum at 60°C for 6 h.
  • Example 3 Preparation of a composition comprising Sunitinib base, L-malic acid and fumaric acid form Gamma 1
  • Atty Docket No. 70175.0023WOU1 then allowed to cool down to room temperature. Crystals formed overnight, and were separated by filtration, washed with TBME (5 ml) and air dried.
  • Example 5 Preparation of composition of sunitinib, L-malic acid and L-tartric acid (form Gamma 3)
  • Example 7 Preparation of composition of sunitinib. L-malic acid and malonic acid (form Gamma 5)
  • Atty Docket No. 70175.0023WOU1 then allowed to cool.
  • the mixture was further cooled to -30°C, and the resulting frozen mixture was lyophilized at 1 mBar.
  • Example 8 Preparation of composition of sunitinib, L-malic acid and adipic acid (form Gamma 6)
  • Sunitinib malate 150 mg, Form I was dissolved in boiling dioxane/water (10 ml, 1 : 1).
  • Adipic acid 55 mg, molar ratio of components is 1 : 1 : 1) was added.
  • the resulting mixture was heated to reflux for 3 min, and then allowed to cool.
  • the mixture was further cooled to -30°C, and the resulting frozen mixture was lyophilized at 1 mBar.
  • Example 9 Preparation of composition of sunitinib, L-malic acid and fumaric acid (form Gamma 7)
  • Sunitinib malate 150 mg, Form I was dissolved in boiling dioxane/water (10 ml, 1 : 1). Fumaric acid (45 mg, molar ratio of components is 1 : 1 : 1) was added. The resulting mixture was heated to reflux for 3 min, and then allowed to cool. The mixture was further cooled to -30°C, and the resulting frozen mixture was lyophilized at 1 mBar.
  • Example 10 Preparation of composition of sunitinib, L-malic acid and fumaric acid (form Gamma 8)
  • Sunitinib malate 150 mg, Form I was dissolved in boiling water (10 ml). Fumaric acid (45 mg, molar ratio of components is 1 : 1 : 1) was added. The resulting mixture was heated to reflux for 3 min, and then allowed to cool. The mixture was further cooled to -30°C, and the resulting frozen mixture was lyophilized at 1 mBar.
  • Atty Docket No. 70175.0023WOU1 was allowed to stand for 3 hrs at 20°C. Crystals formed and were collected by filtration, washed with t-BME (5 ml) and air dried for 3 hrs at 20°C.
  • Crystalline D,L-malic acid (3.3 g) was added to form a suspension.
  • the suspension was heated for an additional 10 min to the reflux temperature facilitating complete dissolution.
  • the solution was allowed to cool to 20°C and stand for 12 h at 20°C. Crystals formed and were collected by filtration, washed with t-BME (50 ml) and air dried for 3 h at 20°C.
  • Sunitinib acetate form Beta (900 mg) was dissolved in 1-butanol (6 ml) by heating to 117° C for 10 min. A solution of D,L-malic acid (300 mg ) in water (0.8 ml) was added. The resulting solution was heated for an additional 10 min and allowed to cool to 20 °C and stand 3 hrs at 20° C. Crystals formed and were collected by filtration, washed with t-BME (20 ml) and air dried for 3 hrs at 20° C.
  • Sunitinib acetate Form a (900 mg) was dissolved in 1 butanol (5 ml) by heating to 117 °C for 10 min. A solution of D,L-malic acid (300 mg ) in water (0.8 ml) was added. The resulting solution was heated for an additional 10 min and allowed to cool to 20 °C and stand 3 hrs at 20 °C. Crystals formed and were collected by filtration, washed with t-BME (20 ml) and air dried for 3 hrs at 20 °C.
  • Sunitinib base obtained by reaction of Sunitinib activated carboxylic acid derivative with excess of N, N'-diethylaminoethylamine in 2- methyltetrahydrofuran, was dissolved in 15 volumes of water (150ml for lOg of sunitinib base) at pH 2 (obtained by addition of HQ 1M) at 70°C. The mixture was then cooled to 25°C and precipitated by adding ammonia (30%) sufficient to raise the pH to 8.5 at 25°C. The resulting mixture was stirred for one hour and filtered at 25°C. The collected solid was washed with water and dried in an oven under vacuum for 16 hours at 60°C.
  • the temperature was set at 70°C and at this temperature, 5.1 g. of thionyl chloride (ratio 1.4/1.0 w/w) were dropped in a range of sixty minutes.
  • the reaction was kept at 70°C for 7 hours under stirring.
  • the mixture was filtered using a decalite pad to obtain a clarified phase.
  • the two phases were separated at 50°C and the organic phase discarded.
  • the aqueous phase was washed once more with 300ml of Methyl-tetrahydrofuran at 50°C under stirring.
  • the two phases separated again and the organic phase discarded.
  • the aqueous phase was then basified to pH 8.5 with 5% ammonia solution at 50 °C.
  • the suspension was filtered on gooch P3 and the wet solid dried at 60°C under vacuum overnight. 15.9 g. of sunitinib base were obtained with a purity of not less than (NLT) 99.5% by HPLC.

Abstract

L'invention porte sur des polymorphes de malate de sunitinib et d'autres sels. L'invention porte également sur des compositions qui comportent du sunitinib base, de l'acide L-malique et un autre acide carboxylique. De tels polymorphes et de telles compositions sont utiles, par exemple, dans la préparation de compositions pharmaceutiques.
PCT/US2011/024194 2010-02-09 2011-02-09 Polymorphes de sels de sunitinib WO2011100325A2 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US30261910P 2010-02-09 2010-02-09
US61/302,619 2010-02-09
US30564710P 2010-02-18 2010-02-18
US61/305,647 2010-02-18
US30660110P 2010-02-22 2010-02-22
US61/306,601 2010-02-22
US34801510P 2010-05-25 2010-05-25
US61/348,015 2010-05-25
US35209010P 2010-06-07 2010-06-07
US61/352,090 2010-06-07
US36071110P 2010-07-01 2010-07-01
US61/360,711 2010-07-01

Publications (2)

Publication Number Publication Date
WO2011100325A2 true WO2011100325A2 (fr) 2011-08-18
WO2011100325A3 WO2011100325A3 (fr) 2011-12-15

Family

ID=43899612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024194 WO2011100325A2 (fr) 2010-02-09 2011-02-09 Polymorphes de sels de sunitinib

Country Status (1)

Country Link
WO (1) WO2011100325A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140232A1 (fr) 2012-03-23 2013-09-26 Laurus Labs Private Limited Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
WO2015031604A1 (fr) 2013-08-28 2015-03-05 Crown Bioscience, Inc. Signatures d'expression génique permettant de prédire la réponse d'un sujet à un inhibiteur multikinase et leurs procédés d'utilisation

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016305A1 (fr) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2009067686A2 (fr) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
WO2009074862A1 (fr) 2007-12-12 2009-06-18 Medichem S.A. Formes polymorphes d'une 2-indolinone substituée par 3-pyrrole
WO2009104021A2 (fr) 2008-02-21 2009-08-27 Generics [Uk] Limited Nouveaux polymorphes et procédés de préparation
WO2009109388A1 (fr) 2008-03-06 2009-09-11 Ratiopharm Gmbh Formes cristallines du n-[2-(diéthylamino)éthyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidène)méthyl]-2,4-diméthyl-1h-pyrrol-3-carboxamide et procédés pour leur préparation
WO2009128083A1 (fr) 2008-04-16 2009-10-22 Natco Pharma Limited Nouvelles formes polymorphes du sunitinib base
WO2009156837A2 (fr) 2008-06-26 2009-12-30 Medichem, S.A. Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010011834A2 (fr) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib et ses sels et leurs polymorphes
WO2010010454A2 (fr) 2008-07-24 2010-01-28 Medichem, S.A. Formes cristallines d’un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010049449A2 (fr) 2008-10-28 2010-05-06 Lek Pharmaceuticals D.D. Nouveaux sels de sunitinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009286521A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2003016305A1 (fr) 2001-08-15 2003-02-27 Pharmacia & Upjohn Company Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes
WO2009067686A2 (fr) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
WO2009067674A2 (fr) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphes de base de sunitinib et procédés pour les préparer
WO2009074862A1 (fr) 2007-12-12 2009-06-18 Medichem S.A. Formes polymorphes d'une 2-indolinone substituée par 3-pyrrole
WO2009104021A2 (fr) 2008-02-21 2009-08-27 Generics [Uk] Limited Nouveaux polymorphes et procédés de préparation
WO2009109388A1 (fr) 2008-03-06 2009-09-11 Ratiopharm Gmbh Formes cristallines du n-[2-(diéthylamino)éthyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidène)méthyl]-2,4-diméthyl-1h-pyrrol-3-carboxamide et procédés pour leur préparation
WO2009128083A1 (fr) 2008-04-16 2009-10-22 Natco Pharma Limited Nouvelles formes polymorphes du sunitinib base
WO2009156837A2 (fr) 2008-06-26 2009-12-30 Medichem, S.A. Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010011834A2 (fr) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib et ses sels et leurs polymorphes
WO2010010454A2 (fr) 2008-07-24 2010-01-28 Medichem, S.A. Formes cristallines d’un sel de malate de 2-indolinone à substitution 3-pyrrole
WO2010049449A2 (fr) 2008-10-28 2010-05-06 Lek Pharmaceuticals D.D. Nouveaux sels de sunitinib

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140232A1 (fr) 2012-03-23 2013-09-26 Laurus Labs Private Limited Procédé perfectionné pour la préparation de sunitinib et de ses sels d'addition avec un acide
WO2015031604A1 (fr) 2013-08-28 2015-03-05 Crown Bioscience, Inc. Signatures d'expression génique permettant de prédire la réponse d'un sujet à un inhibiteur multikinase et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2011100325A3 (fr) 2011-12-15

Similar Documents

Publication Publication Date Title
EP2253629A1 (fr) Polymorphes de malate de sunitinib racémique, compositions les contenant et leur préparation
US9895377B2 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US8937082B2 (en) Nilotinib salts and crystalline forms thereof
US8703967B2 (en) Crystal form of sunitinib malate
US9067915B2 (en) Sunitinib and salts thereof and their polymorphs
US8329740B2 (en) Polymorphs of sunitinib malate
JP2011512396A (ja) 新規な多形およびその調製方法
US20120029046A1 (en) Crystalline form of sunitinib and processes for its preparation
WO2017160703A1 (fr) Formes solides de sels de nilotinib
WO2011100325A2 (fr) Polymorphes de sels de sunitinib
WO2011092664A1 (fr) Formes cristallines du sel d'acide l-malique du sunitinib
KR20220016949A (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
AU2004215407B2 (en) Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2016172333A1 (fr) Forme à l'état solide de pérampanel
US7452913B2 (en) Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2012125993A1 (fr) Formes à l'état solide de base rilpivirine et sels de rilpivirine
CN102239163A (zh) 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
WO2017035170A1 (fr) Formes à l'état solide de maléate de cédiranib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11704515

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11704515

Country of ref document: EP

Kind code of ref document: A2